Up-regulated Golgi phosphoprotein 2 (GOLPH2) expression in lung adenocarcinoma tissue

Clinical Biochemistry

Volumn 43, Issue 12, 2010, Pages 983-991

  Zhang, Fangfang ^a,b   Gu, Yanli ^a   Li, Xiang ^a   Wang, Wei ^a   He, Jianxing ^c   Peng, Tao ^a,b  

^a GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^b UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^c GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Adenocarcinoma; GOLPH2 GP73 GOLM1; Immunochemistry; Lung cancer; Sandwich ELISA; Tissue marker

Indexed keywords

GOLGI PHOSPHOPROTEIN 2; MEMBRANE PROTEIN; MONOCLONAL ANTIBODY; PHOSPHOPROTEIN; UNCLASSIFIED DRUG; GOLM1 PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GOLGI COMPLEX; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; SERUM; ADENOCARCINOMA; CONFOCAL MICROSCOPY; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; IN VITRO STUDY; LUNG TUMOR; METABOLISM; MIDDLE AGED; TUMOR CELL LINE; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MICROSCOPY, CONFOCAL; MIDDLE AGED; YOUNG ADULT; IN VITRO TECHNIQUES;

EID: 77954315629     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.05.010     Document Type: Article

References (41)

1. Kladney R.D., Bulla G.A., Guo L., Mason A.L., Tollefson A.E., Simon D.J., et al. GP73, a novel Golgi-localized protein upregulated by viral infection. Gene 2000, 249:53-65.
2. Kladney R.D., Cui X., Bulla G.A., Brunt E.M., Fimmel C.J. Expression of GP73, a resident Golgi membrane protein, in viral and nonviral liver disease. Hepatology 2002, 35:1431-1440.
3. Iftikhar R., Kladney R.D., Havlioglu N., Schmitt-Graff A., Gusmirovic I., Solomon H., et al. Disease- and cell-specific expression of GP73 in human liver disease. Am J Gastroenterol 2004, 99:1087-1095.
4. Li H., Wetten S., Li L., St Jean P.L., Upmanyu R., Surh L., et al. Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol 2008, 65:45-53.
5. Wright L.M., Huster D., Lutsenko S., Wrba F., Ferenci P., Fimmel C.J. Hepatocyte GP73 expression in Wilson disease. J Hepatol 2009, 51:557-564.
6. Luo J.H., Yu Y.P., Cieply K., Lin F., Deflavia P., Dhir R., et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002, 33:25-35.
7. Laxman B., Morris D.S., Yu J., Siddiqui J., Cao J., Mehra R., et al. A first-generation multiplex biomarker analysis of urine for the early detection of prostate cancer. Cancer Res 2008, 68:645-649.
8. Kristiansen G., Fritzsche F.R., Wassermann K., Jager C., Toelle A., Lein M., et al. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics. Br J Cancer 2008, 99:939-948.
9. Wei S.Z., Dunn T.A., Isaacs W.B., De Marzo A.M., Luo J. GOLPH2 and MYO6: putative prostate cancer markers localized to the Golgi apparatus. Prostate 2008, 68:1387-1395.
10. Varambally S., Laxman B., Mehra R., Cao Q., Dhanasekaran S., Tomlins S.A., et al. Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia 2008, 10:1285-U1104.
11. Fritzsche F.R., Riener M.O., Dietel M., Moch H., Jung K., Kristiansen G. GOLPH2 expression in renal cell cancer. BMC Urol 2008, 8:1471-2490.
12. Block T.M., Comunale M.A., Lowman M., Steel L.F., Romano P.R., Fimmel C., et al. Use of targeted glycoproteomics to identify serum glycoproteins that correlate with liver cancer in woodchucks and humans. Proc Natl Acad Sci USA 2005, 102:779-784.
13. Marrero J.A., Romano P.R., Nikolaeva O., Steel L., Mehta A., Fimmel C.J., et al. GP73, a resident Golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol 2005, 43:1007-1012.
14. Marrero J.A., Lok A.S.F. Newer markers for hepatocellular carcinoma. Gastroenterology 2004, 127:S113-S119.
15. Mao Y.L., Yang H.Y., Xu H.F., Sang X.T., Lu X., Yang Z.Y., et al. Significance of Golgi glycoprotein 73, a new tumor marker in diagnosis of hepatocellular carcinoma: a primary study. Zhonghua Yi Xue Za Zhi 2008, 88:948-951.
16. Norton P.A., Comunale M.A., Krakover J., Rodemich L., Pirog N., D'Amelio A., et al. N-linked glycosylation of the liver cancer biomarker GP73. J Cell Biochem 2008, 104:136-149.
17. Gu Y., Chen W., Zhao Y., Chen L., Peng T. Quantitative analysis of elevated serum Golgi protein-73 expression in patients with liver diseases. Ann Clin Biochem 2009, 46:38-43.
18. Riener M.O., Stenner F., Liewen H., Soll C., Breitenstein S., Pestalozzi B.C. Golgi phosphoprotein 2 (GOLPH2) expression in liver tumors and its value as a serum marker in hepatocellular carcinomas. Hepatology 2009, 49:1602-1609.
19. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of eighteen major cancers in 1985. Int J Cancer 1993, 54:594-606.
20. Garcia M., Jemal A., Ward E.M., Center M.M., Hao Y., Siegel R.L., et al. Global Cancer Facts & Figures 2007 2007, American Cancer Society, Atlanta, GA.
21. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002, CA. Cancer J Clin 2005, 55:74-108.
22. American Cancer Society Cancer Facts & Figures 2009 2009, American Cancer Society, Atlanta.
23. Wakelee H.A., Bernardo P., Johnson D.H., Schiller J.H. Changes in the natural history of nonsmall cell lung cancer (NSCLC) - Comparison of outcomes and characteristics in patients with advanced NSCLC entered in Eastern Cooperative Oncology Group trials before and after 1990. Cancer 2006, 106:2208-2217.
24. Yang P., Allen M.S., Aubry M.C., Wampfler J.A., Marks R.S., Edell E.S., et al. Clinical features of 5, 628 primary lung cancer patients-experience at Mayo clinic from 1997 to 2003. Chest 2005, 128:452-462.
25. Govindan R., Page N., Morgensztern D., Read W., Tierney R., Vlahiotis A., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006, 24:4539-4544.
26. Harlow E.L.D. Using antibodies: a laboratory manual 1999, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
27. Brambilla E., Travis W.D., Colby T.V., Corrin B., Shimosato Y. The new World Health Organization classification of lung tumours. Eur Respir J 2001, 18:1059-1068.
28. Mountain C.F. Revisions in the International System for Staging Lung Cancer. Chest 1997, 111:1710-1717.
29. Bennis F., Favre G., Legaillard F., Soula G. Importance of mevalonate-derived products in the control of Hmg-Coa reductase-activity and growth of human lung adenocarcinoma cell-line A549. Int J Cancer 1993, 55:640-645.
30. Wang J.F., Huang C.Y., Xu J.Y., Xiong Y., Zhao Q. Serophysiological study on the effects of high-fat diet on proliferation of human lung adenocarcinoma cell line SPCA1. Wei Sheng Yan Jiu 2006, 35:39-42.
31. Wang H. Establishment of two human pulmonary adenocarcinoma cell lines (LTEP-a-1, LTEP-a-2) and their biologic properties. Zhonghua Zhong Liu Za Zhi 1983, 5:85-88.
32. Liang M.D. Establishment of lung adenocarcinoma cell line in Gejiu (GLC-82) and study of its biologic properties. Zhonghua Zhong Liu Za Zhi 1985, 7:81-82.
33. Jin Y., Yan C.H., Wu Y., Liu Y., Zhang G.Y., Li P., et al. Research on expression and control of p16 and p21 by wild-type p53 gene in two lung adenocarcinoma cell lines. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 2003, 20:409-412.
34. Wang H., Lai B.T., Guo Y.H. Establishment of human pulmonary squamous cell cancer cell line (LTEP-78) and observation on its biologic properties (author's transl). Zhonghua Zhong Liu Za Zhi 1980, 2:241-246.
35. Osaki S., Nakanishi Y., Takayama K., Pei X.H., Ueno H., Hara N. Alteration of drug chemosensitivity caused by the adenovirus-mediated transfer of the wild-type p53 gene in human lung cancer cells. Cancer Gene Ther 2000, 7:300-307.
36. Block T.M., Marrero J., Gish R.G., Sherman M., London W.T., Srivastava S., et al. The degree of readiness of selected biomarkers for the early detection of hepatocellular carcinoma: notes from a recent workshop. Cancer Biomark 2008, 4:19-33.
37. Lu Y., Yi Y., Liu P., Wen W., James M., Wang D., et al. Common human cancer genes discovered by integrated gene-expression analysis. PLoS One 2007, 2:e1149.
38. Munro S. Localization of proteins to the Golgi apparatus. Trends Cell Biol 1998, 8:11-15.
39. Puri S., Bachert C., Fimmel C.J., Linstedt A.D. Cycling of early Golgi proteins via the cell surface and endosomes upon lumenal pH disruption. Traffic 2002, 3:641-653.
40. Bachert C., Fimmel C., Linstedt A.D. Endosomal trafficking and proprotein convertase cleavage of cis Golgi protein GP73 produces marker for hepatocellular carcinoma. Traffic 2007, 8:1415-1423.
41. Wright L.M., Yong S., Picken M.M., Rockey D., Fimmel C.J. Decreased survival and hepato-renal pathology in mice with c-terminally truncated GP73 (GOLPH2). Int J Clin Exp Pathol 2009, 2:34-47.